Imagenebio Stock Today
| IMA Stock | 6.91 0.10 1.43% |
PerformanceWeakest
| Odds Of DistressSmall
|
ImageneBio is trading at 6.91 as of the 6th of February 2026, a 1.43% down since the beginning of the trading day. The stock's open price was 7.01. ImageneBio has about a 43 percent probability of financial distress in the next few years of operation and has generated negative returns over the last 90 days. ImageneBio symbol was changed from IKNA on 28th of July 2025. The performance scores are derived for the period starting the 8th of November 2025 and ending today, the 6th of February 2026. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 26th of March 2021 | Category Healthcare | Classification Health Care |
ImageneBio is entity of United States. It is traded as Stock on NASDAQ exchange. The company has 11.18 M outstanding shares of which 384.41 K shares are currently shorted by investors with about 1.31 days to cover. More on ImageneBio
Moving together with ImageneBio Stock
Moving against ImageneBio Stock
ImageneBio Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| Older Symbol | IKNA | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| CEO Director | Kristin Yarema | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Old Name | I Minerals | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsImageneBio can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand ImageneBio's financial leverage. It provides some insight into what part of ImageneBio's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ImageneBio (IMA) is traded on NASDAQ Exchange in USA and employs 9 people. ImageneBio was previously known as Ikena Oncology and was traded on NASDAQ Exchange under the symbol IKNA. ImageneBio is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a total capitalization of 91.69 M. ImageneBio runs under Biotechnology sector within Health Care industry. The entity has 11.18 M outstanding shares of which 384.41 K shares are currently shorted by investors with about 1.31 days to cover.
ImageneBio generates negative cash flow from operations
Check ImageneBio Probability Of Bankruptcy
Ownership AllocationThe market capitalization of ImageneBio is USD91.69 Million. 30% of ImageneBio outstanding shares are owned by outside corporations. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.
Check ImageneBio Ownership Details
ImageneBio Historical Income Statement
ImageneBio Stock Against Markets
ImageneBio Corporate Management
| Anna MD | Senior Development | Profile | |
| Kurinji Pandiyan | Chief Officer | Profile | |
| Yufang MD | Chief Officer | Profile | |
| Renuka Sivendran | Chief Officer | Profile | |
| Erin Butler | Senior Administration | Profile |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in ImageneBio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in industry. For information on how to trade ImageneBio Stock refer to our How to Trade ImageneBio Stock guide.You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ImageneBio. Market participants price ImageneBio higher when confident in its future expansion prospects. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive ImageneBio assessment requires weighing all these inputs, though not all factors influence outcomes equally.
ImageneBio's market price often diverges from its book value, the accounting figure shown on ImageneBio's balance sheet. Smart investors calculate ImageneBio's intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Since ImageneBio's trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Please note, there is a significant difference between ImageneBio's value and its price as these two are different measures arrived at by different means. Investors typically determine if ImageneBio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ImageneBio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.